AlphaGenome Atlas: Mapping Every Possible DNA Variant
Google DeepMind’s AlphaGenome Atlas maps all nine billion possible DNA variants, helping researchers rapidly prioritise disease-linked mutations.
Machine Learning in Drug Discovery: Gains and Data Gaps
Machine learning in drug discovery promises faster drug screening and fewer failures, but weak data limits gains. See what the latest 2026 review means for pharma.
AI Biology: What Biohub’s $1.8bn Push Means for Pharma
In one of the most important developments, AI biology gets a $1.8 billion boost as Biohub, DOE, and the NIH build open and AI-ready data for virtual cell models.
Target Atlas for Smarter Target Prioritisation for Parkinson’s
Target prioritisation gets an evidence upgrade. Find out how Phylo’s Target Atlas and the MJFF Parkinson’s edition rank disease drug targets.
Novo Bets on AI Drug Discovery as GLP-1 Patents Near Expiry
AI drug discovery is moving into strategy at Novo. See its 2026 AI milestones, what they prove, and the questions R&D teams should ask before copying them.
The Cursed Little Black Box of the AI Algorithm
Explore the black-box problem in AI-driven drug discovery, including interpretability, data quality, reproducibility, and the evidence needed to trust predictions.